CN101821289A - 重组制造抗rsv抗体的方法 - Google Patents

重组制造抗rsv抗体的方法 Download PDF

Info

Publication number
CN101821289A
CN101821289A CN200880106131A CN200880106131A CN101821289A CN 101821289 A CN101821289 A CN 101821289A CN 200880106131 A CN200880106131 A CN 200880106131A CN 200880106131 A CN200880106131 A CN 200880106131A CN 101821289 A CN101821289 A CN 101821289A
Authority
CN
China
Prior art keywords
clone
antibody
cell
ser
rsv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880106131A
Other languages
English (en)
Chinese (zh)
Inventor
安妮·B·托尔斯特拉普
约翰·兰托
芬恩·威伯格
拉斯·S·尼尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Symphogen AS
Original Assignee
Symphogen AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen AS filed Critical Symphogen AS
Publication of CN101821289A publication Critical patent/CN101821289A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN200880106131A 2007-09-07 2008-09-04 重组制造抗rsv抗体的方法 Pending CN101821289A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200701289 2007-09-07
DKPA200701289 2007-09-07
US97140407P 2007-09-11 2007-09-11
US60/971,404 2007-09-11
PCT/DK2008/050218 WO2009030237A2 (en) 2007-09-07 2008-09-04 Methods for recombinant manufacturing of anti-rsv antibodies

Publications (1)

Publication Number Publication Date
CN101821289A true CN101821289A (zh) 2010-09-01

Family

ID=40297785

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880106131A Pending CN101821289A (zh) 2007-09-07 2008-09-04 重组制造抗rsv抗体的方法

Country Status (13)

Country Link
US (2) US20090137003A1 (https=)
EP (1) EP2185590A2 (https=)
JP (1) JP2011514139A (https=)
KR (1) KR20100087283A (https=)
CN (1) CN101821289A (https=)
AU (1) AU2008295248A1 (https=)
BR (1) BRPI0817079A2 (https=)
CA (1) CA2695309A1 (https=)
MX (1) MX2010002044A (https=)
RU (1) RU2010113510A (https=)
TW (1) TW200925279A (https=)
WO (1) WO2009030237A2 (https=)
ZA (1) ZA201000756B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111330017A (zh) * 2012-08-23 2020-06-26 艾更斯司股份有限公司 结合158p1d7蛋白的抗体药物偶联物(adc)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2444695T3 (es) * 2006-06-23 2014-02-26 Alethia Biotherapeutics Inc. Polinucleótidos y polipéptidos implicados en el cáncer
DK2121920T3 (da) * 2007-03-01 2011-11-21 Symphogen As Fremgangsmåde til kloning af sammenhørende antistoffer
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
CN102137928A (zh) * 2008-08-29 2011-07-27 西福根有限公司 克隆禽源抗体的方法
CA2740900C (en) 2008-11-03 2019-09-24 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of a tumor antigen
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
JP5762408B2 (ja) * 2009-08-13 2015-08-12 クルセル ホランド ベー ヴェー ヒト呼吸器合胞体ウイルス（ｒｓｖ）に対する抗体および使用方法
EP2486053B1 (en) * 2009-10-06 2017-01-18 Medimmune Limited Rsv-specific binding molecule
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
CN104628850B (zh) * 2009-10-06 2020-07-28 医学免疫有限公司 Rsv-特异性结合分子
ES2724975T3 (es) 2009-12-10 2019-09-18 Regeneron Pharma Ratones que producen anticuerpos de cadena pesada
BR112012031638B1 (pt) 2010-07-09 2021-01-12 Janssen Vaccines & Prevention B.V. anticorpo anti-rsv ou fragmento de ligação de antígeno do mesmo, anticorpo multivalente, composição farmacêutica, uso de anticorpo ou fragmento de ligação de antígeno, método de detectar infecção por rsv, e, ácido nucleico isolado
SI3173427T1 (sl) 2011-03-31 2019-08-30 ADC Therapeutics SA, Protitelesa proti antigenu 1, povezanemu z ledvicami, in antigen vezavni fragmenti le-tega
KR102102239B1 (ko) 2012-01-09 2020-04-21 에이디씨 테라퓨틱스 에스에이 유방암을 치료하기 위한 방법
JP5996707B2 (ja) * 2015-04-15 2016-09-21 メディミューン リミテド Ｒｓｖ特異的結合分子
SG11201708804WA (en) 2015-05-07 2017-11-29 Agenus Inc Anti-ox40 antibodies and methods of use thereof
MA43389A (fr) * 2015-12-02 2021-05-12 Agenus Inc Anticorps anti-ox40 et leurs procédés d'utilisation
AU2016364891A1 (en) * 2015-12-03 2018-06-07 Agenus Inc. Anti-OX40 antibodies and methods of use thereof
CN110035771B (zh) * 2016-10-21 2024-03-08 阿迪马布有限责任公司 抗呼吸道合胞病毒抗体及其产生和使用方法
AU2017345786B2 (en) 2016-10-21 2024-08-01 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
US11479600B2 (en) 2016-10-21 2022-10-25 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
WO2018150029A1 (en) * 2017-02-17 2018-08-23 Institut Pasteur Generation of monoclonal antibodies targeting respiratory syncytial virus (rsv) using regulatory b cells from newborns (nbregs)
CN113728003A (zh) 2019-04-30 2021-11-30 吉加根公司 重组多克隆蛋白及其使用方法
WO2021202463A1 (en) 2020-03-30 2021-10-07 Danisco Us Inc Anti-rsv antibodies
WO2021253002A1 (en) 2020-06-12 2021-12-16 Gigagen, Inc. Recombinant polyclonal proteins targeting covid-19 and methods of use thereof
WO2022031834A1 (en) * 2020-08-05 2022-02-10 Gigagen, Inc. Recombinant polyclonal proteins targeting zika and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060275766A1 (en) * 2003-01-07 2006-12-07 Haurum John S Method for manufacturing recombinant polyclonal proteins
TWI333977B (en) * 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
US8288109B2 (en) * 2004-07-20 2012-10-16 Symphogen A/S Procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line
EA014182B1 (ru) * 2004-07-20 2010-10-29 Симфоген А/С КОМПОЗИЦИЯ ПОЛИКЛОНАЛЬНЫХ АНТИ-RhD АНТИТЕЛ, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ КОМПОЗИЦИИ
US7850965B2 (en) * 2005-12-05 2010-12-14 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
WO2007101441A1 (en) * 2006-03-06 2007-09-13 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
JP2010534057A (ja) * 2007-03-06 2010-11-04 シムフォゲン・アクティーゼルスカブ 呼吸器合胞体ウイルス感染症を治療するための組換え抗体
MX2009012526A (es) * 2007-05-25 2009-12-09 Symphogen As Metodo para fabricar una proteina policlonal recombinante.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111330017A (zh) * 2012-08-23 2020-06-26 艾更斯司股份有限公司 结合158p1d7蛋白的抗体药物偶联物(adc)

Also Published As

Publication number Publication date
BRPI0817079A2 (pt) 2016-10-11
CA2695309A1 (en) 2009-03-12
US20090137003A1 (en) 2009-05-28
WO2009030237A2 (en) 2009-03-12
RU2010113510A (ru) 2011-10-20
AU2008295248A1 (en) 2009-03-12
ZA201000756B (en) 2010-10-27
JP2011514139A (ja) 2011-05-06
EP2185590A2 (en) 2010-05-19
WO2009030237A3 (en) 2009-04-30
KR20100087283A (ko) 2010-08-04
TW200925279A (en) 2009-06-16
MX2010002044A (es) 2010-03-18
US20120009623A1 (en) 2012-01-12

Similar Documents

Publication Publication Date Title
CN101821289A (zh) 重组制造抗rsv抗体的方法
KR20080113223A (ko) 호흡기세포 융합 바이러스 감염 치료용 재조합 폴리클로날 항체
KR20090127341A (ko) 호흡기세포 융합 바이러스 감염 치료용 재조합 항체
AU2019246763B2 (en) Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
KR20230002261A (ko) 항-sars-cov-2 중화 항체 및 이의 사용 방법
CN109414455B (zh) Bcma结合分子及其使用方法
CN106924729B (zh) 人巨细胞病毒中和抗体及其应用
KR20070038556A (ko) 항-ｒｈｅｓｕｓ ｄ 재조합 폴리클로날 항체 및 이의 제조방법
US7141653B2 (en) Human monoclonal antibodies to interleukin-5
AU2024200534A1 (en) Anti-TL1A/anti-TNF-alpha bispecific antigen binding proteins and uses thereof
CN107406504B (zh) Ctla-4抗体及其用途
CN112262156B (zh) 抗her2抗体
KR101937733B1 (ko) 광견병 감염의 방지 및 치료에 관한 조성물 및 방법
JP2009518320A (ja) 抗オルトポックスウイルス組換えポリクローナル抗体
CN107406508A (zh) 人源化的抗trop‑2单克隆抗体及其应用
CN113402602B (zh) 一种新型冠状病毒SARS-CoV-2中和性抗体及应用
KR101900435B1 (ko) 인간 사이토메갈로바이러스 gB 단백질에 대한 고친화도 인간 항체
CN101023101A (zh) 抗－恒河猴d重组多克隆抗体和生产方法
CN114685653B (zh) 抗新冠病毒受体结合区域表位中和抗体及其应用
KR102467943B1 (ko) 항-rsv 항체 및 이를 포함하는 약학적 조성물
AU2004236263A1 (en) Compositions and methods for treatment of cryptococcosis
US12358971B2 (en) Arena virus monoclonal antibodies and uses
HK40000650B (en) Bcma binding molecules and methods of use thereof
MXPA05011989A (en) Compositions and methods for treatment of cryptococcosis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100901